Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy.

Hiley CT, Swanton C.

Cancer Discov. 2016 Feb;6(2):122-4. doi: 10.1158/2159-8290.CD-15-1493.

2.

Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.

Beránek M, Sirák I, Vošmik M, Petera J, Drastíková M, Palička V.

Acta Medica (Hradec Kralove). 2016;59(2):54-8. doi: 10.14712/18059694.2016.54.

3.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

4.

SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing.

Niknafs N, Beleva-Guthrie V, Naiman DQ, Karchin R.

PLoS Comput Biol. 2015 Oct 5;11(10):e1004416. doi: 10.1371/journal.pcbi.1004416. eCollection 2015 Oct.

5.

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.

Bratman SV, Newman AM, Alizadeh AA, Diehn M.

Expert Rev Mol Diagn. 2015 Jun;15(6):715-9. doi: 10.1586/14737159.2015.1019476. Epub 2015 Mar 16. Review.

6.

Circulating tumor DNA: new horizons for improving cancer treatment.

Lianos GD, Mangano A, Cho WC, Dionigi G, Roukos DH.

Future Oncol. 2015;11(4):545-8. doi: 10.2217/fon.14.250. No abstract available.

7.

Next generation sequencing and urologic cancer.

Kim SK, Kim WJ.

Korean J Urol. 2015 Feb;56(2):87-9. doi: 10.4111/kju.2015.56.2.87. No abstract available.

8.

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.

9.

Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.

Siravegna G, Bardelli A.

Mol Oncol. 2016 Mar;10(3):475-80. doi: 10.1016/j.molonc.2015.12.005. Epub 2015 Dec 17. Review.

10.

Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era.

Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ.

PLoS One. 2015 May 14;10(5):e0126670. doi: 10.1371/journal.pone.0126670. eCollection 2015.

11.

Generation of high quality chromatin immunoprecipitation DNA template for high-throughput sequencing (ChIP-seq).

Deliard S, Zhao J, Xia Q, Grant SF.

J Vis Exp. 2013 Apr 19;(74). doi: 10.3791/50286.

12.

[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].

Pécuchet N, Legras A, Laurent-Puig P, Blons H.

Ann Pathol. 2016 Jan;36(1):80-93. doi: 10.1016/j.annpat.2015.11.012. Epub 2016 Jan 20. French.

PMID:
26803564
13.

Genome sequencing and cancer.

Mardis ER.

Curr Opin Genet Dev. 2012 Jun;22(3):245-50. doi: 10.1016/j.gde.2012.03.005. Epub 2012 Apr 23. Review.

14.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.

Oncotarget. 2016 Jan 19;7(3):3453-60. doi: 10.18632/oncotarget.6498.

15.

Defining the genomic landscape of head and neck cancers through next-generation sequencing.

Rizzo G, Black M, Mymryk JS, Barrett JW, Nichols AC.

Oral Dis. 2015 Jan;21(1):e11-24. doi: 10.1111/odi.12246. Epub 2014 Apr 30. Review.

PMID:
24725020
16.

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.

Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, Koeppen H, Tam R, Schleifman E, Mashhedi H, Chalasani S, Fu L, Sumiyoshi T, Raja R, Forrest W, Hampton GM, Lackner MR, Hegde P, Jia S.

Oncologist. 2014 Apr;19(4):336-43. doi: 10.1634/theoncologist.2013-0180. Epub 2014 Mar 24.

17.

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?

Ignatiadis M, Dawson SJ.

Ann Oncol. 2014 Dec;25(12):2304-13. doi: 10.1093/annonc/mdu480. Epub 2014 Oct 21. Review.

PMID:
25336116
18.

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Int J Cancer. 2013 Jul 15;133(2):346-56. doi: 10.1002/ijc.28030. Epub 2013 Feb 13.

19.

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.

Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT.

Mod Pathol. 2015 Oct;28(10):1390-9. doi: 10.1038/modpathol.2015.86. Epub 2015 Jul 31.

20.

Genome-wide detection of single-nucleotide and copy-number variations of a single human cell.

Zong C, Lu S, Chapman AR, Xie XS.

Science. 2012 Dec 21;338(6114):1622-6. doi: 10.1126/science.1229164.

Supplemental Content

Support Center